“We’re probably not even through the first inning of what we’re going to learn here,” said Wendy Holman, CEO of Ridgeback Biotherapeutics, which is working with Merck & Co. on an antiviral drug against COVID-19. Holman spoke during a Fierce JPM Week panel on COVID-19 therapeutics Monday.
I posted this morning that the Ridgeback/Merck therapeutic is one to keep an eye on. IPIX better put on their cleats and take the field if they want to be in this game.